Introducing JULUCA▼ (dolutegravir/rilpivirine) for your virologically suppressed adult HIV patients1
Watch this short video (2 min 30 s) with Dr Marty St. Clair discussing the resistance profile of JULUCA and the reasons behind pairing DTG with RPV.
JULUCA is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1
JULUCA is owned by or licensed to the ViiV Healthcare group of companies.
©2018 ViiV Healthcare group of companies or its licensor.